HGProject reference: 718642
Funded under :
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
Real-time molecular diagnostic testing for human infectious diseases using LAMP (Loop Mediated Isothermal Amplification) technology.
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Call for proposal:H2020-SMEINST-1-2015See other projects for this call
Funding scheme:SME-1 - SME instrument phase 1
Roughly 85% of small & medium sized hospitals remain without molecular diagnostics capabilities for human infectious diseases. Current solutions are expensive or have complex workflows and therefore have been unable to penetrate this large market segment. This is a key issue resulting in a more costly healthcare system and reducing efficiency when such testing must be carried out offsite rather than in-house. As accurate diagnostic results take longer to produce this can have a major negative impact on a patient’s health, particularly when urgent diagnosis and appropriate care may be required.
The in vitro HG diagnostics system, consisting of the portable testing device (HG Swift) as well as freeze dried reagents, is cost-effective and makes molecular diagnostics accessible to a laboratory or near patient environment such as an A&E or maternity labour ward with minimal training required. Furthermore the HG system is unique, producing highly accurate and rapid results (less than 60 minutes “sample to result”) and is flexible, capable of testing for multiple human infectious diseases.
Once the HG solution has been commercialised, Hibergene can address the unmet needs of the large unmet market segment of small to medium sized hospitals by improving patient diagnosis and helping to create a more efficient healthcare system overall.
EU contribution: EUR 50 000
21 PALMERSTOWN GARDENS - RATHMINES
DUBLIN 6 DUBLIN